By staff writers
March 1, 2017

GE Healthcare is launching its new Clariscan (gadoteric acid) MRI contrast agent at this week's ECR 2017 meeting in Vienna.

The gadolinium-based contrast agent (GBCA) is designed to visualize abnormalities in the brain, spine, and associated tissues. The macrocyclic and ionic contrast agent will be available in a range of doses in vials and prefilled syringes, and it joins the company's linear GBCA Omniscan, which has been used for MR imaging for more than 25 years.

Thus far, Clariscan has received approval for marketing and distribution in Norway. GE plans to introduce the new contrast agent to the rest of Europe this year.

Reports: GE to move healthcare workers to Chicago
GE Healthcare is planning to move "hundreds" of workers from the suburban Chicago location of Barrington, IL, to its recently opened headquarters in the...
Lantheus inks deal with GE for flurpiridaz PET tracer
Lantheus Medical Imaging has signed a term sheet with GE Healthcare to support the worldwide development and commercialization of its flurpiridaz F-18...
GE scores FDA OK for CT spectral imaging
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Gemstone spectral imaging Xtream technology on its...
GE to modernize five Kuwait hospitals
GE Healthcare is partnering with Advanced Technology Co. (ATC) to bring advanced diagnostic imaging and digital technology to five new Ministry of Health...
NBA, GE partner on bone stress injuries
GE Healthcare and the NBA are partnering to focus on bone stress injuries, issuing a call for proposals for research studies investigating the issue.

Copyright © 2017

Last Updated np 3/1/2017 1:02:32 PM